EGRX Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc. to Present at 42nd Annual Deutsche Bank Health Care Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference as follows:

             
Date: Thursday, May 4, 2017
 
Time: 10:00 a.m. EDT
 
Location:

The InterContinental Boston Hotel

 

The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the company’s website at www.eagleus.com, under the Investors Section and is also available at http://edge.media-server.com/m/p/m7pheguw.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
24/04/2017

Underlying

EGRXEagle Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

Eagle Pharmaceuticals Announces Divestiture of Barhemsys WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatme...

January 14, 2026 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Right...

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the...

October 30, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stoc...

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results ...

October 21, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quart...

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at . About Eagle Pharmaceuticals, Inc.Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in...

October 15, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarte...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at . About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meani...

October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch